On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Grey Cloak Tech Inc. (GRCK) is “One to Watch”

  • Actively executing its growth-by-acquisition strategy, building a portfolio of clinically proven, naturally formulated supplements
  • The BergaMet NA brand is well-positioned for growth throughout North America with its proprietary 47% BPF formulations developed for cardiovascular health, women’s health, immune support, sports performance and recovery
  • UBN subsidiary, with its KETONOMICS(R) proprietary formulation, is well-aligned with Grey Cloak’s corporate strategy to provide better lifestyles through superior health technology.
  • KETONOMICS(R) is medical and scientific research that focuses on the field of brain and physiological metabolism which provides proprietary positions
  • UBN has five unique formulation patents – one issued and four pending – targeting brain activity, focus, headache and cognitive behavior. These patents provide protection for proprietary formulas

Grey Cloak Tech (OTC: GRCK), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health technology

BergaMet North America

BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit(TM) called “bergamot.” Bergamot is native to Southern Italy and is naturally sourced and uniquely loaded with various antioxidant polyphenols. Thanks to this composition, bergamot supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.

BergaMet NA is the only Citrus Bergamot SuperFruit(TM) heart health supplement backed by 17 clinical studies. The BergaMet brand supplement boasts the highest quality and concentration of polyphenols and flavonoids available anywhere in the world. It is also the only bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. BergaMet NA is the only company authorized to manufacture, distribute and sell these products in the United States, Canada and Mexico.

Consumers are including the Citrus Bergamot SuperFruit(TM) in their everyday personal health programs. The clinically proven antioxidant provides benefits to tens of thousands of people daily.

The company’s line of products can be found at www.BergaMetNA.com, through Amazon, other online retailers and in doctors’ offices throughout the United States.

The BergaMet Advantage

BergaMet has been studied in 17 published clinical trials which reported results of lower LDL cholesterol, higher HDL cholesterol, lower triglycerides, lower blood pressure, lower blood glucose, increased arterial function, improved liver function and is effective as a complement to statin use.

Cardiovascular disease is the number one cause of death in the U.S. and worldwide, claiming nearly 18 million lives each year accounting for 31% of all global deaths. In the U.S., statins are one of the most commonly prescribed medicines for cardiovascular disease. The Centers for Disease Control estimates that 28% of American women and men over the age of 40 take a statin to lower the amount of cholesterol in the blood.

Taking aim at this market for cardiovascular care, BergaMet NA continues to advance the awareness of its medical-grade supplements and separate its formulation from competitors.

BergaMet NA products contain 47% BPF (bergamot polyphenolic fraction), while its closest competitors have only 38%. The company’s increased dosages (600-675mg vs 500mg) and 47% BPF are clinically proven to be more effective in improving heart health and metabolic syndrome.

BergaMet Citrus Bergamot SuperFruit(TM) supplements:

  • Support healthy immune systems with powerful antioxidants and proprietary formulations
  • Reduce cholesterol and support healthy glucose and blood pressure levels
  • Are fully organic, vegan-friendly and dairy, gluten, soy and GMO-free
  • Contain five key unique flavonoids that make up the most powerful 47% BPF (bergamot polyphenolic fraction) in the world, providing superior results compared to their competitors
  • Have been clinically shown to increase arterial elasticity while reducing arterial and muscle inflammation

Ultimate Brain Nutrients

Grey Cloak’s Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy.

UBN’s KETONOMICS(R) proprietary formulations – targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio.

License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms.

UBN has five unique formulation patents – one issued and four pending – targeting brain activity, focus, headache and cognitive behavior.

The UBN Advantage

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research and are positioned to provide consumer neuro-products that are natural brain solutions. UBN has filed for approval to the U.S. Food and Drug Administration (“FDA”) to make a Qualified Health Claim for its migraine formulation, tapping into consumer demands for healthy beverages that contribute to brain health, overall well-being and performance.

Over 50 million Americans consume unhealthy energy shots and drinks each day, while the neuro/energy market generates over $10 billion per year in revenue. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy, science-based options. The company’s KETONOMICS(R) proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

UBN’s KETONOMICS(R) supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

Grey Cloak Executive Team

Kevin “Duke” Pitts, Director, President and Chief Operating Officer

  • Started and built from the ground up two multi-million-dollar businesses, one of which grew into a Top 100 retailers in the U.S.
  • Unique management skills led to the development of successful teams for 35 years
  • Pioneered direct marketing for a Fortune 200 company, creating a 20% increase in targeted incremental sales
  • Founded Einstein’s Hemp, which developed and brought to market one of the only odorless and tasteless water-soluble CBD products in the world
  • Developed and implemented digital/guerrilla marketing strategies for public and private companies focused on long-term brand position and acquisition efforts
  • Specialized in customer relationship management (“CRM”) tools for creating the best customer experiences
  • Worked in publicly traded industries for 10 years, overseeing up to $20 million in annual marketing budgets

William “Bill” Bossung, Director, Chief Financial Officer

  • 35 years of diverse experience in corporate finance, insurance and accounting
  • 20 years of experience with IPOs focusing on audits, FINRA and SEC regulations
  • Specializes in the formation of capital raising over $100 million, recently raising $12 million for Splash Beverage
  • Specializes in upgrading penny stocks companies to the NYSE or Nasdaq
  • Involved in 30+ companies transitioning from private to public identities
  • Founded several companies, including BCF Technology Inc., which sold to Vertafore; managing partner at Bishop Equity Partners LLC; director at Splash Beverage Group; and director of finance at Chadmoore Wireless, where he licensed channels to Nextel for $162 million

Bill Croyle, Director, Private Investor and Accomplished Senior Executive

  • More than 40 years of success in the IT, energy, manufacturing, telecommunications, venture capital and finance industries
  • Broad expertise includes negotiating mergers and acquisitions, as well as service and delivery contracts
  • Formerly was a founder, owner or executive of EnTX Group; Impact Legacy Partners; FB Oilfield Special Tools; and Western Energy Advisors

Dr. Gerald Haase, Chief Medical Officer

  • Clinical professor of surgery at the University of Colorado, School of Medicine
  • Actively involved in medical research and clinical trials for 35 years
  • Received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program, as well as U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA
  • Was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado; consultant surgeon to the Department of the Army; vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute; on the National Board of Directors of the American Cancer Society; a senior member of the Commission on Cancer of the American College of Surgeons; and a member of the editorial board of The Annals of Surgical Oncology
  • Has published 180 scientific papers and is the inventor or co-inventor of 12 issued U.S. patents for micronutrient and phytonutrient therapy, with five pending patents
  • Recipient of clinical research grants and contracts funded at a several million-dollar cumulative level
  • Is an editorial reviewer for medical journals and a member of numerous professional societies, including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences and American College of Physician Executives

For more information, visit the company’s website at www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GRCK are available in the company’s newsroom

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered